Novel mucolytic agents
AssigneeParion Sciences, Inc.
InventorsMichael R. JOHNSON, William R. THELIN, Richard C. BOUCHER, Diane VILLALON, Jone L. BOYER
Life of this patent
Estimating the term…
Abstract
Provided is a method of liquefying mucus from mucosal surfaces by administering compounds containing a phosphine group.
Claims24
A method of liquefying mucus from mucosal surfaces, comprising:
- administering an effective amount of the compound of Formula I to a mucosal surface of a subject.
- R is independently selected from —OH, phenyl, —NR1R1, —CO2R1
- R1 is independently selected from H and C1-C8 alkyl,
- n is an integer from 0-6 with the proviso that there are three carbon-phosphorous single bonds
A method of treating chronic bronchitis, treating bronchiectasis, treating cystic fibrosis, treating chronic obstructive pulmonary disease, treating asthma, treating sinusitis, treating vaginal dryness, treating dry eye, promoting ocular hydration, promoting corneal hydration, promoting mucus clearance in mucosal surfaces, treating Sjogren's disease, treating distal intestinal obstruction syndrome, treating dry skin, treating esophagitis, treating dry mouth, treating nasal dehydration, treating ventilator-induced pneumonia, treating asthma, treating primary ciliary dyskinesia, treating otitis media, inducing sputum for diagnostic purposes, treating cystinosis, treating emphysema, treating pneumonia, treating constipation, treating chronic diverticulitis, and/or treating rhinosinusitis, comprising:
- administering an effective amount of the compound of Formula 1 to a subject in need thereof.
A method of treating an eye disease characterized by the presence of ocular discharge consisting of administering to a subject in need an effective amount of a mucolytic agent according to Formula 1.
A method of treating a disease ameliorated by increased mucociliary clearance and mucosal hydration comprising administering to a subject in need of increased mucociliary clearance and mucosal hydration an effective amount of an osmolyte and the compound of Formula 1.
A composition, comprising:
- (a) the compound of Formula 1 and (b) an osmotically active compound.
A method of inducing sputum, comprising administering to a subject in need of increased mucociliary clearance and mucosal hydration an effective amount of an osmolyte and the compound of Formula 1.
A method of prophylactic, post-exposure prophylactic, preventive or therapeutic treatment against diseases or conditions caused by pathogens, comprising administering to a subject in need of increased mucociliary clearance and mucosal hydration an effective amount of a compound of Formula 1.
A method for preventing, mitigating, and/or treating deterministic health effects to the respiratory tract and/or other bodily organs caused by respirable aerosols containing radionuclides in a human in need thereof, said method comprising administering to said human an effective amount of a compound according to Formula 1, or a pharmaceutically acceptable salt thereof.
A pharmaceutical composition, comprising the compound of Formula 1 and a pharmaceutically acceptable carrier.
A method for improving mucus penetration of therapeutic agents comprising administering an effective amount of a compound of Formula 1 and a second therapeutic agent.
A method for decreasing mucosal inflammation comprising administering an effective amount of a compound of Formula 1.
A method for decreasing mucosal oxygen free radicals comprising administering an effective amount of a compound of Formula 1.
Dependencies are inferred from the claim text.